Reply: DAPT Shortening After Complex PCI: Examining the Fine Print

Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration

doi:10.1016/j.jacc.2023.03.425

Reply: DAPT Shortening After Complex PCI: Examining the Fine Print

Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	e193
Journal	Journal of the American College of Cardiology
Volume	81
Issue number	22
DOIs	https://doi.org/10.1016/j.jacc.2023.03.425
State	Published - 6 Jun 2023

Access to Document

10.1016/j.jacc.2023.03.425

Cite this

@article{163794c265854e708c62bae723c74db8,

title = "Reply: DAPT Shortening After Complex PCI: Examining the Fine Print",

author = "{Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration} and Felice Gragnano and Roxana Mehran and Paolo Calabr{\`o} and Marco Valgimigli",

note = "Funding Information: This study was funded by institutional support of the Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, which had no role in the data analysis, interpretation, or writing of the report. There was no industry involvement in the design, analysis, or funding of this study. Dr Mehran has received institutional research payments from Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, AtriCure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi-Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia, Janssen, Magenta, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, and Zoll; has received personal fees from Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, and WebMD; has equity of <1% in Applied Therapeutics, Elixir Medical, Stel, and ControlRad (spouse); has served on Scientific Advisory Boards for AMA, ACC (Board of Trustees Member), and SCAI (Women in Innovations Committee Member); is an Associate Editor for JAMA Cardiology; and is a faculty member for the Cardiovascular Research Foundation (no fee). Dr Valgimigli has received grants and personal fees from Terumo; and has received personal fees from AstraZeneca, Alvimedica/CID, Abbott Vascular, Daiichi-Sankyo, Bayer, CoreFlow, Idorsia Pharmaceuticals, Universit{\"a}t Basel Dept Klinische Forschung, Bristol Myers Squibb, Medscape, Biotronik, and Novartis, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2023",

month = jun,

day = "6",

doi = "10.1016/j.jacc.2023.03.425",

language = "English",

volume = "81",

pages = "e193",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "22",

}

TY - JOUR

T1 - Reply

T2 - DAPT Shortening After Complex PCI: Examining the Fine Print

AU - Single Versus Dual Antiplatelet Therapy (Sidney-2) Collaboration

AU - Gragnano, Felice

AU - Mehran, Roxana

AU - Calabrò, Paolo

AU - Valgimigli, Marco

N1 - Funding Information: This study was funded by institutional support of the Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, which had no role in the data analysis, interpretation, or writing of the report. There was no industry involvement in the design, analysis, or funding of this study. Dr Mehran has received institutional research payments from Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, AtriCure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi-Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia, Janssen, Magenta, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, and Zoll; has received personal fees from Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, and WebMD; has equity of <1% in Applied Therapeutics, Elixir Medical, Stel, and ControlRad (spouse); has served on Scientific Advisory Boards for AMA, ACC (Board of Trustees Member), and SCAI (Women in Innovations Committee Member); is an Associate Editor for JAMA Cardiology; and is a faculty member for the Cardiovascular Research Foundation (no fee). Dr Valgimigli has received grants and personal fees from Terumo; and has received personal fees from AstraZeneca, Alvimedica/CID, Abbott Vascular, Daiichi-Sankyo, Bayer, CoreFlow, Idorsia Pharmaceuticals, Universität Basel Dept Klinische Forschung, Bristol Myers Squibb, Medscape, Biotronik, and Novartis, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2023/6/6

Y1 - 2023/6/6

UR - http://www.scopus.com/inward/record.url?scp=85160276369&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2023.03.425

DO - 10.1016/j.jacc.2023.03.425

M3 - Letter

AN - SCOPUS:85160276369

SN - 0735-1097

VL - 81

SP - e193

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 22

ER -